Pharmacovigilance principles

Pharmacovigilance - The Drug Watchdogs

• The science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem.
• Post-marketing surveillance (Phase IV) is critical as pre-marketing trials (Phases I-III) have limited size and duration, often missing rare or long-term adverse drug reactions (ADRs).
• Key Systems:
  • FDA MedWatch: A voluntary reporting system for healthcare professionals and consumers to report serious adverse events.
  • FAERS (FDA Adverse Event Reporting System): A database containing adverse event reports and medication errors.

⭐ Signals from MedWatch can lead to regulatory actions, including updating a drug’s label, issuing safety communications, or, in rare cases, drug withdrawal. It is the nation's primary system for this purpose.

Reporting & Detection - Spotting the Signal

• Spontaneous Reporting Systems (SRS): The foundation of post-marketing surveillance.
  • Key US System: FDA MedWatch program.
  • Database: Reports are compiled into the FDA Adverse Event Reporting System (FAERS).
  • Reporters: Clinicians, patients, and manufacturers.
• Signal: A reported association between a drug and an adverse event, suggesting a potential causal link that requires further investigation.
• Signal Detection: Primarily achieved through data mining of SRS databases like FAERS.
  • Limitation: Cannot prove causality or calculate true incidence due to variable reporting quality and under-reporting (denominator unknown).

⭐ The Weber Effect describes the peak in adverse event reporting for a new drug within the first 2 years of marketing, followed by a decline.

Causality & Phases - The Blame Game

• Causality Assessment: Establishes if a drug caused an Adverse Drug Reaction (ADR).

  • Naranjo Algorithm: Widely used scoring tool to determine likelihood (definite, probable, possible).
  • Key Factors: Temporal relationship, dose-response, dechallenge/rechallenge.

• Clinical Trial Phases: 📌 Mnemonic: Safe? Works? Improvement? Market?

⭐ Phase IV (Post-marketing surveillance) is critical for identifying rare, long-latency adverse effects that were not detected in pre-market trials.

Regulatory Actions - Dropping the Hammer

• FDA's Enforcement Toolkit: Based on post-marketing surveillance data (FAERS, MedWatch), the FDA can take escalating actions to manage drug risk.
• Key Interventions:
  • Labeling Changes: Updates to prescribing information (e.g., new contraindications, warnings).
  • Boxed Warning (Black Box Warning): Strongest warning for drugs with serious or life-threatening risks.
  • Risk Evaluation and Mitigation Strategy (REMS): Required for certain high-risk drugs to ensure benefits outweigh risks. May involve special certification or patient monitoring.

⭐ High-Yield: A Boxed Warning is the FDA's most serious warning. It is used when a drug has a significant risk of serious or life-threatening adverse effects. Prescribers must assess if the benefits of using the drug outweigh these substantial risks for their patient.

High‑Yield Points - ⚡ Biggest Takeaways

• Pharmacovigilance is the science and activity relating to the detection, assessment, understanding, and prevention of adverse effects.
• Post-marketing surveillance (Phase IV) is essential to detect rare or long-latency adverse drug reactions (ADRs) not seen in smaller pre-market trials.
• The FDA's MedWatch program is a cornerstone, relying on voluntary reporting from clinicians and patients.
• Signal detection is the process of identifying potential new causal links between drugs and adverse events.
• Regulatory actions may include label changes, risk communications, or adding a Black Box Warning-the strongest available.
• A major limitation of all spontaneous reporting systems is under-reporting.